Abstract:Background Accumulating evidence has shown that tumor-associated macrophages (TAMs) play a critical role in tumor progression. Targeting TAMs is a potential strategy for tumor immunotherapy. However, the mechanism underlying the TAM phenotype and function needs to be resolved. Our previous studies have demonstrated that miR-125a can reverse the TAM phenotype toward antitumor. Meanwhile, we have found that miR-125a and miR-99b cluster in the first intron of the same host gene, and are transcribed simultaneously in bone marrow-derived macrophages (BMDMs) following LPS+IFNγ stimulation. However, it remains unclear whether miR-99b by itself can exert an antitumor effect by regulating macrophage phenotype. Methods miR-99b and/or miR-125a were delivered into TAMs of orthotopic hepatocellular carcinoma (HCC) or subcutaneous Lewis lung cancer (LLC) mice. The effect of treatment was evaluated by live imaging, TUNEL staining and survival tests. The phenotype of the immune cells was determined by qRT-PCR, ELISA, western blot and FACS. The capability of miR-99b-mediated macrophage phagocytosis and antigen presentation was detected by FACS and immunofluorescence staining. The underlying molecular mechanism was examined by qRT-PCR, reporter assay and western blot, and further verified in the tumor model. The expression of miR-99b and its target genes was determined in TAMs sorted from tumor and adjacent tissues in patients with liver cancer. Results Targeted delivery of miR-99b and/or miR-125a into TAMs significantly impeded the growth of HCC and LLC, especially after miR-99b delivery. More importantly, the delivery of miR-99b re-educated TAM toward antitumor phenotype with enhanced immune surveillance. Further investigation of mechanisms showed that macrophage-specific overexpression of miR-99b promoted M1 while suppressing M2 macrophage polarization by targeting κB-Ras2 and/or mTOR, respectively. miR-99b-overexpressed M1 macrophage was characterized by stronger capability of phagocytosis and antigen presentation. Additionally, delivery of simTOR or siκB-Ras2 into TAMs inhibited miR-99b antagomir-triggered tumor growth. Finally, miR-99b expression was lower in TAMs of patients with liver cancer than that in adjacent tissues, while the expression of κB-Ras2 and mTOR was reversed. Conclusions Our results reveal the mechanism of miR-99b-mediated TAM phenotype, indicating that TAM-targeted delivery of miR-99b is a potential strategy for cancer immunotherapy.

MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

A Mir-125B/csf1-cx3cl1/tumor-associated Macrophage Recruitment Axis Controls Testicular Germ Cell Tumor Growth

MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT

MicroRNA-126 regulates the induction and function of CD4+ Foxp3+ regulatory T cells through PI3K/AKT pathway

Mir-125B-5p Inhibits Cell Proliferation, Migration, and Invasion in Hepatocellular Carcinoma Via Targeting TXNRD1.

Mir-125B is Methylated and Functions As a Tumor Suppressor by Regulating the ETS1 Proto-Oncogene in Human Invasive Breast Cancer.

Targeted delivery of miR-99b reprograms tumor-associated macrophage phenotype leading to tumor regression

Tumor-secreted Mir-214 Induces Regulatory T Cells: a Major Link Between Immune Evasion and Tumor Growth

MiR-1254 Suppresses HO-1 Expression Through Seed Region-Dependent Silencing and Non-Seed Interaction with TFAP2A Transcript to Attenuate NSCLC Growth

Suppression of Microrna-125A-5p Upregulates the TAZ-EGFR Signaling Pathway and Promotes Retinoblastoma Proliferation

Data from Mir-125B is Methylated and Functions As a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer

Progress on the Relationship Between Mir-125 Family and Tumorigenesis

Mir-125a-3p Inhibits Er Alpha Transactivation And Overrides Tamoxifen Resistance By Targeting Cdk3 In Estrogen Receptor-Positive Breast Cancer

Mir-125B Expression Affects Tumor Growth of Multiple Myeloma Via Targeting MKK7.

MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis.

Microrna-200c Promotes Suppressive Potential Of Myeloid-Derived Suppressor Cells By Modulating Pten And Fog2 Expression

A Cellular MicroRNA Facilitates Regulatory T Lymphocyte Development by Targeting the FOXP3 Promoter TATA-Box Motif.

Correction: Mir-135B Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer.

MicroRNA-125b Promotes Tumor Metastasis Through Targeting Tumor Protein 53-Induced Nuclear Protein 1 in Patients with Non-Small-cell Lung Cancer

MiR-125a-5p Decreases the Sensitivity of Treg cells Toward IL-6-Mediated Conversion by Inhibiting IL-6R and STAT3 Expression